» Articles » PMID: 29610508

ACG Clinical Guideline: Management of Crohn's Disease in Adults

Overview
Specialty Gastroenterology
Date 2018 Apr 4
PMID 29610508
Citations 501
Authors
Affiliations
Soon will be listed here.
Abstract

Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn's disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn's disease has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology and were developed under the auspices of the Practice Parameters Committee for the management of adult patients with Crohn's disease. These guidelines are established for clinical practice with the intent of suggesting preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When exercising clinical judgment, health-care providers should incorporate this guideline along with patient's needs, desires, and their values in order to fully and appropriately care for patients with Crohn's disease. This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated. To evaluate the level of evidence and strength of recommendations, we used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fields. The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time.

Citing Articles

To cut or not to cut? Extended mesenteric excision during intestinal resection does not impact the postoperative recurrence nor the postoperative complications in Crohn's disease: a systematic review and meta-analysis.

Topala M, Martinekova P, Rancz A, Veres D, Lenti K, Miheller P Tech Coloproctol. 2025; 29(1):79.

PMID: 40057619 PMC: 11890256. DOI: 10.1007/s10151-025-03110-w.


The relationships between depression, inflammation and self-reported disease activity in IBD and their impact on healthcare usage.

Seaton N, Wileman V, Norton C, Hudson J, Mondelli V, Moss-Morris R BMC Gastroenterol. 2025; 25(1):140.

PMID: 40050710 PMC: 11883936. DOI: 10.1186/s12876-025-03691-8.


Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.

Akiyama S, Hayashi R, Takasago T, Kusunoki K, Ikeuchi H, Takenaka K J Gastroenterol. 2025; .

PMID: 40050487 DOI: 10.1007/s00535-025-02231-1.


The patient and clinician perspective on 'early' bowel resection for terminal ileal Crohn's disease (EBRIC): protocol for a multicentre mixed-methods study.

Husnoo N, Wyld L, Lobo A, Morgan J, Hawkins D, Hunt L Colorectal Dis. 2025; 27(3):e70042.

PMID: 40025798 PMC: 11873672. DOI: 10.1111/codi.70042.


Unravelling the implementation of pharmacogenetic testing in Belgium.

Bourgeois J, Costa E, Devos C, Luyten J, Ombelet S, Thiry N Eur J Clin Pharmacol. 2025; .

PMID: 40019504 DOI: 10.1007/s00228-025-03816-8.


References
1.
Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C . Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol. 2012; 18(32):4391-8. PMC: 3436056. DOI: 10.3748/wjg.v18.i32.4391. View

2.
Roberts R, Gearry R, Hollis-Moffatt J, Miller A, Reid J, Abkevich V . IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol. 2007; 102(12):2754-61. DOI: 10.1111/j.1572-0241.2007.01525.x. View

3.
Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G . Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996; 39(1):82-6. PMC: 1383237. DOI: 10.1136/gut.39.1.82. View

4.
Gutierrez A, Lee H, Sands B . Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol. 2006; 101(10):2283-9. DOI: 10.1111/j.1572-0241.2006.00757.x. View

5.
Vermeire S, Van Assche G, Rutgeerts P . C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10(5):661-5. DOI: 10.1097/00054725-200409000-00026. View